induced pluripotent stem cells

[ALPHAMED PRESS (EurekAlert!)] Dr. Lin Ma is the recipient of STEM CELLS’s Young Investigator Award for 2021. Her work on engineering hypoimmunogenic human PSCs exemplifies the potential of the field and promise of this young next generation of researchers.

[Cytovia Therapeutics, Inc. (GlobeNewswire, Inc.)] Cytovia Therapeutics, Inc. and Cellectis announced that they have expanded their collaboration of TALEN® gene-edited iPSC-derived natural killer (NK) and chimeric antigen receptor (CAR)-NK cells to include new CAR target and development in China by Cytovia’s joint venture entity, CytoLynx Therapeutics.

[Cell Reports] In cell transplantation therapy for spinal cord injury, grafted human induced pluripotent stem cell-derived neural stem/progenitor cells (hiPSC-NS/PCs) differentiate into neurons. Scientists found that chemogenetic stimulation of hiPSC-derived neural cells enhancesd cell activity and neuron-to-neuron interactions in vitro.

[Molecular Therapy-Nucleic Acids] The authors provided proof of principle that allele-specific lowering of polyQ-expanded ataxin-3 by selective antisense oligonucleotides was feasible and long lasting with sparing of wildtype ataxin-3 expression in a human cell culture model that was genetically identical to spinocerebellar ataxia type 3 (SCA3) patients.

[NPJ Regenerative Medicine] Investigators described the development, transcriptomic ontogenetic characterization and quality assessment at the single cell level, as well as the scaled manufacturing of an allogeneic human PSC-derived articular chondrocyte formulation that exhibited long-term functional repair of porcine articular cartilage.

[Stem Cell Research & Therapy] Scientists genetically modified human iPSCs with a zinc finger nuclease technology to introduce a cDNA encoding an anti-EpCAM chimeric antigen receptor into the adeno-associated virus integration site 1, a “safe harbour” for transgene insertion into human genome.